Pharma BD Deal Intelligence
AstraZeneca's $2.3B restructuring gave it global commercialization lead and a favorable economics shift on tezepelumab (Tezspire), paying Amgen $575M upfront to move off a 50/50 US split. The realigned asthma and nasal polyps franchise has since scored strongly, marking the renegotiation a clear win for AstraZeneca.
AstraZeneca and Amgen restructured their existing collaboration for tezepelumab (Tezspire), an anti-TSLP antibody for severe asthma. Under the updated terms, AstraZeneca made a $575M payment to Amgen to increase its share of tezepelumab economics (moving from 50/50 US split to AZ-favorable terms). Total consideration to Amgen across the original and restructured deals is approximately $2.3B including royalties. AZ gained global commercialization lead.
2.5M US cases/yr · $12.0B Global Severe Asthma Market (2024)
Severe asthma ~10% of patients, disproportionate morbidity. Tezepelumab (Tezspire) targets TSLP upstream of multiple inflammatory pathways.
Sanofi/Regeneron (Dupixent $13B+), GSK (Nucala), AZ (Fasenra), Novartis (Xolair). Tezspire's broad mechanism its key differentiator.
2M US cases/yr · $1.9B Global CRSwNP Market (2024)
CRSwNP chronic inflammatory condition. Biologics expanded beyond surgical polypectomy.
Sanofi/Regeneron (Dupixent) leads. Novartis (Xolair), GSK (Nucala) approved. ~6.5% CAGR.
AZ paid $575M to increase Tezspire economics. Equal profit share after mid-single-digit royalty to Amgen.
FDA approved Tezspire on Dec 17, 2021 for severe asthma in patients 12+, validating the AZ-Amgen collaboration as a commercial success. First-in-class TSLP blocker.
Tezspire generated $1.2B in 2024 combined sales. Approved in 60+ countries for severe asthma and CRSwNP.
Tezspire hit blockbuster status. Approved for asthma + CRSwNP. COPD trials underway for further expansion.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AstraZeneca PLC / Amgen Inc. (this deal) | 2020 | $2.3B | 84 |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| AstraZeneca PLC / KuDOS Pharmaceuticals Limited | 2005 | $210M | 98 |
| AstraZeneca PLC / Alexion Pharmaceuticals Inc. | 2020 | $39.0B | 86 |
| AstraZeneca PLC / Acerta Pharma | 2015 | $4.0B | 86 |
| AstraZeneca PLC / MedImmune Inc. | 2007 | $15.6B | 82 |
| AstraZeneca PLC / CinCor Pharma Inc. | 2023 | $1.8B | 78 |
← Browse all deals · How we score deals
More: 2020 deals · AstraZeneca PLC deals · Respiratory deals